GS-US-595-6184 || A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician s Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05 / OptimICE-RD)

A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician s Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05 / OptimICE-RD)

Learn more:
http://www.clinicaltrials.gov/ct2/show/NCT05633654

Protocol Number

C-510

Phase

III

Management Group

Oncology Network

Oncology Group

Breast Oncology Group

Disease Sites

Breast

Sponsor Protocol

GS-US-595-6184

Principal Investigator

Amelia Zelnak

Scope

National

Participating Institutions

Atlanta Cancer Care - Atlanta
Atlanta Cancer Care - Cumming
Georgia Cancer Specialists - Blairsville
Georgia Cancer Specialists - Canton
Georgia Cancer Specialists - Decatur
Georgia Cancer Specialists - Macon
Georgia Cancer Specialists - Marietta
Georgia Cancer Specialists - Northside
Suburban Hematology Oncology Associates - Duluth
Suburban Hematology Oncology Associates - Lawrenceville

Find Open Clinical Trials

A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician s Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05 / OptimICE-RD)

Want to learn more?